About this Journal Submit a Manuscript Table of Contents
Journal of Ophthalmology
Volume 2013 (2013), Article ID 529187, 4 pages
Clinical Study

18-Fluorodeoxyglucose Uptake by Positron Emission Tomography in Extraocular Muscles of Patients with and without Graves' Ophthalmology

1Instituto de Oftalmología “Fundación de Asistencia Privada Conde de Valenciana I.A.P.”, 06800 Mexico City, DF, Mexico
2Unidad PET/CT Ciclotrón, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510 Mexico City, DF, Mexico

Received 17 August 2012; Revised 5 December 2012; Accepted 9 January 2013

Academic Editor: Lawrence S. Morse

Copyright © 2013 Leonardo García-Rojas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Garrity and R. S. Bahn, “Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment,” American Journal of Ophthalmology, vol. 142, no. 1, pp. 147–153, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. R. S. Bahn and A. E. Heufelder, “Pathogenesis of Graves' ophthalmopathy,” New England Journal of Medicine, vol. 329, no. 20, pp. 1468–1475, 1993. View at Publisher · View at Google Scholar · View at Scopus
  3. G. B. Bartley, “The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmstead County, Minnesota,” Transactions of the American Ophthalmological Society, vol. 92, pp. 477–588, 1994. View at Scopus
  4. R. S. Bahn, “Graves’ Ophthalmopathy,” New England Journal of Medicine, vol. 362, pp. 726–738, 2010.
  5. J. Pritchard, R. Han, N. Horst, W. W. Cruikshank, and T. J. Smith, “Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway,” Journal of Immunology, vol. 170, no. 12, pp. 6348–6354, 2003. View at Scopus
  6. P. J. Dolman and J. Rootman, “VISA classification for graves orbitopathy,” Ophthalmic Plastic and Reconstructive Surgery, vol. 22, no. 5, pp. 319–324, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. G. Lee, P. W. Brazis, J. A. Garrity, and M. White, “Imaging for neuro-ophthalmic and orbital disease,” American Journal of Ophthalmology, vol. 138, no. 5, pp. 852–862, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. G. El-Haddad, H. Zhuang, N. Gupta, and A. Alavi, “Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders,” Seminars in Nuclear Medicine, vol. 34, no. 4, pp. 313–329, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. R. D. Finn, “The search for consistency in the manufacture of PET radiopharmaceuticals,” Annals of Nuclear Medicine, vol. 13, no. 6, pp. 379–382, 1999. View at Scopus
  10. K. R. Zasadny and R. L. Wahl, “Standardized uptake values of normal tissues at PET with 2-[fluorine-18]- fluoro-2-deoxy-D-glucose: Variations with body weight and a method for correction,” Radiology, vol. 189, no. 3, pp. 847–850, 1993. View at Scopus
  11. S. Osman and H. J. Danpure, “The use of 2-[18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography,” International Journal of Radiation Applications and Instrumentation B, vol. 19, no. 2, pp. 183–190, 1992. View at Publisher · View at Google Scholar · View at Scopus
  12. L. A. Forstrom, B. P. Mullan, J. C. Hung, V. J. Lowe, and L. M. Thorson, “18F-FDG labelling of human leukocytes,” Nuclear Medicine Communications, vol. 21, no. 7, pp. 691–694, 2000. View at Scopus
  13. T. Ishimori, T. Saga, M. Mamede et al., “Increased 18F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation,” Journal of Nuclear Medicine, vol. 43, no. 5, pp. 658–663, 2002. View at Scopus
  14. P. H. Kuo, T. Monchamp, and P. Deol, “Imaging of inflammation in Graves' ophthalmopathy by positron emission tomography/computed tomography,” Thyroid, vol. 16, no. 4, pp. 419–420, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. S. C. Burrell and A. D. van den Abbeele, “2-deoxy-2-[F-18]fluoro-D-glucose—positron emission tomography of the head and neck: an atlas of normal uptake and variants,” Molecular Imaging and Biology, vol. 7, no. 3, pp. 244–256, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Zincirkeser, E. Şahin, M. Halac, and S. Sager, “Standardized uptake values of normal organs on 18F-fluorodeoxyglucose positron emission tomography and computed tomography imaging,” Journal of International Medical Research, vol. 35, no. 2, pp. 231–236, 2007. View at Scopus
  17. H. Uematsu, N. Sadato, Y. Yonekura et al., “Coregistration of FDG PET and MRI of the head and neck using normal distribution of FDG,” Journal of Nuclear Medicine, vol. 39, no. 12, pp. 2121–2127, 1998. View at Scopus
  18. S. Nakamura, K. Okochi, Y. Murata, H. Shibuya, and T. Kurabayashi, “[18F]Fluorodeoxyglucose-PET/CT differentiation between physiological and pathological accumulations in head and neck,” Nuclear Medicine Communications, vol. 30, no. 7, pp. 498–503, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Meller, F. Strutz, U. Siefker et al., “Early diagnosis and follow-up of aortitis with [18F]FDG PET and MRI,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 5, pp. 730–736, 2003. View at Scopus